ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 308 filers reported holding ACADIA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.65 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,033,705 | -9.0% | 49,602 | +4.6% | 0.00% | 0.0% |
| Q2 2023 | $1,135,326 | +95.7% | 47,404 | +53.8% | 0.00% | – |
| Q1 2023 | $580,146 | +16.3% | 30,826 | -1.6% | 0.00% | – |
| Q4 2022 | $498,789 | -4.1% | 31,331 | -1.4% | 0.00% | – |
| Q3 2022 | $520,000 | +145.3% | 31,767 | +111.3% | 0.00% | – |
| Q2 2022 | $212,000 | -51.7% | 15,032 | -17.0% | 0.00% | – |
| Q1 2022 | $439,000 | +12.3% | 18,116 | +8.2% | 0.00% | – |
| Q4 2021 | $391,000 | -97.7% | 16,748 | -97.6% | 0.00% | -100.0% |
| Q2 2021 | $17,359,000 | -5.2% | 711,711 | +0.3% | 0.01% | 0.0% |
| Q1 2021 | $18,309,000 | -51.8% | 709,664 | -0.1% | 0.01% | -56.2% |
| Q4 2020 | $37,980,000 | +29.7% | 710,432 | +0.1% | 0.02% | +14.3% |
| Q3 2020 | $29,280,000 | +0.8% | 709,805 | +4.9% | 0.01% | -6.7% |
| Q2 2020 | $29,039,000 | +1.6% | 676,590 | 0.0% | 0.02% | -21.1% |
| Q1 2020 | $28,586,000 | -1.2% | 676,590 | 0.0% | 0.02% | +26.7% |
| Q4 2019 | $28,945,000 | +7.3% | 676,590 | -9.8% | 0.02% | 0.0% |
| Q3 2019 | $26,985,000 | +34.6% | 749,790 | 0.0% | 0.02% | +36.4% |
| Q2 2019 | $20,042,000 | -0.4% | 749,790 | 0.0% | 0.01% | 0.0% |
| Q1 2019 | $20,132,000 | +4000.2% | 749,790 | +2366.9% | 0.01% | – |
| Q4 2018 | $491,000 | -99.0% | 30,394 | -98.6% | 0.00% | -100.0% |
| Q1 2018 | $48,678,000 | -50.1% | 2,166,346 | -33.1% | 0.02% | -46.8% |
| Q4 2017 | $97,492,000 | -15.7% | 3,237,846 | +5.5% | 0.05% | -17.5% |
| Q3 2017 | $115,601,000 | +16.1% | 3,068,789 | -14.0% | 0.06% | +14.0% |
| Q2 2017 | $99,563,000 | -20.8% | 3,569,889 | -2.4% | 0.05% | -21.9% |
| Q1 2017 | $125,709,000 | +3.2% | 3,656,449 | -13.4% | 0.06% | +1.6% |
| Q4 2016 | $121,756,000 | -8.3% | 4,221,789 | +1.1% | 0.06% | -8.7% |
| Q3 2016 | $132,832,000 | +21.5% | 4,175,786 | +24.0% | 0.07% | +16.9% |
| Q2 2016 | $109,283,000 | +51.0% | 3,366,686 | +30.1% | 0.06% | +55.3% |
| Q1 2016 | $72,372,000 | +11.1% | 2,588,417 | +41.6% | 0.04% | +15.2% |
| Q4 2015 | $65,166,000 | +13.3% | 1,827,933 | +5.1% | 0.03% | +17.9% |
| Q3 2015 | $57,501,000 | -44.6% | 1,738,753 | -29.9% | 0.03% | -40.4% |
| Q2 2015 | $103,886,000 | +52.7% | 2,480,553 | +18.9% | 0.05% | +51.6% |
| Q1 2015 | $68,016,000 | +60.6% | 2,087,000 | +56.5% | 0.03% | +63.2% |
| Q4 2014 | $42,339,000 | +15.4% | 1,333,500 | -10.0% | 0.02% | +11.8% |
| Q3 2014 | $36,704,000 | -23.5% | 1,482,400 | -30.2% | 0.02% | -19.0% |
| Q2 2014 | $47,995,000 | +58.5% | 2,124,600 | +70.7% | 0.02% | +50.0% |
| Q1 2014 | $30,286,000 | -11.3% | 1,244,800 | -8.9% | 0.01% | -17.6% |
| Q4 2013 | $34,131,000 | +12.0% | 1,365,800 | +23.2% | 0.02% | +6.2% |
| Q3 2013 | $30,464,000 | +74.8% | 1,109,000 | +15.5% | 0.02% | +60.0% |
| Q2 2013 | $17,428,000 | – | 960,200 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
| Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
| RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
| Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
| Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
| EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
| EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
| SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |